Dare Bioscience, Inc. current report, 23 October 2024

Filing Summary

Company: Dare Bioscience, Inc. Filing: Form 8-K dated October 23, 2024.

Business context and reporting period

Dare entered into a subaward agreement with National Collegiate Inventors and Innovators Alliance, Inc. (d/b/a VentureWell) to support development of DARE-HPV, an investigational vaginal insert intended as an at-home treatment for HPV-related cervical diseases. The 8-K reports the agreement and related award announcement; it is not a periodic financial report.

Financial and operating highlights

  • Dare is eligible to receive up to $10.0 million in milestone-based funding. Payments are conditional on satisfactory performance; the filing does not report cash received or recognize the award as revenue.
  • The agreement has a 24-month performance period beginning October 23, 2024. More than half of the potential award is scheduled to become payable in the first 12 months, subject to performance.
  • The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures.

Milestones, outlook, and risks

Required activities include IND-enabling nonclinical studies, FDA clearance of an IND application, clinical-supply manufacturing milestones, and initiation of a Phase 2 randomized, placebo-controlled, double-blind study evaluating DARE-HPV safety and preliminary efficacy.

ARPA-H retains a nonexclusive license to access and share research results and data, as well as certain intellectual-property rights, including Bayh-Dole march-in rights. During the agreement and for three years afterward, restrictions apply to foreign access to certain technology developed through the work; specified transfers, including a sale of the company or relevant technology, require ARPA-H approval.

The agreement may be terminated under specified circumstances, including termination of the underlying Prime Agreement or certain unresolved performance disputes. Dare cautions that funding and development depend on meeting milestones and that drug development and the company’s ability to continue as a going concern involve risks. The filing gives no separate financial guidance.

Important facts to verify

  • Whether Dare meets the required milestones and receives the potential payments, including the timing and amount of any payments.
  • Whether the underlying Prime Agreement remains in effect and whether any termination provisions are triggered.
  • Progress toward IND clearance, manufacturing milestones, and commencement of the Phase 2 study.
  • The detailed agreement terms when filed with Dare’s fiscal 2024 Form 10-K; the 8-K says certain private or confidential provisions may be omitted.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.